> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Veozah Liver Injury Warning
- URL: https://www.fdaweb.com/fda-veozah-liver-injury-warning/
- Published: 2024-09-12T12:00:00.000Z
- Updated: 2026-09-14T14:41:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157764

FDA has added a Warning to labeling for Astellas’ menopausal hot flashes drug Veozah (fezolinetant) indicating it can cause rare but serious liver injury. A 9/12 [drug safety communication](http://www.fda.gov/media/181764/download?attachment&ref=fdaweb.com) says the agency made the labeling update after reviewing a postmarketing report of a patient with elevated liver blood test values and signs and symptoms of liver injury after taking the drug for about 40 days.

The revised labeling also adds new recommendations for patients and healthcare professionals about increasing the frequency of liver blood testing, adding monthly testing for the next two months after starting Veozah, and then at months 3, 6, and 9 of treatment as already recommended, FDA says.

The updated prescribing information instructs patients to stop the medicine immediately and contact the healthcare professional who prescribed the drug if signs and symptoms of liver injury occur.